RxDoctor Payments Data

Amy Brown, MD

Gynecologic Oncology · Hartford, CTNPI 1518900133

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (59.7%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Tesaro, Inc. accounts for 68.4% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2019 at $16,074 and has fallen 55.3% since, to $7,186 in 2025.

$23,448in general payments, 2019–2025

Across 34 payments — averaging $689.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Tesaro, Inc.$16K
  • Medtronic$7K
  • GSK$40
  • Aspira Women's Health Inc$39
  • Meditrina$29
  • Boehringer Ingelheim$23
  • plus $19 from 1 others
$693,708in research payments, 2019–2025

Across 77 payments — averaging $9009.19 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$355K
  • AstraZeneca$167K
  • Sage Therapeutics, LLC$79K
  • Tesaro, Inc.$65K
  • Medtronic$18K
  • Astrazeneca UK Limited$6K
  • plus $4K from 1 others

What the payments were for

  • Consulting fees$6,50028%
  • Speaking & faculty fees$14,00060%
  • Travel & lodging$1,9218%
  • Food & beverage$9664%
  • Education$610%

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Tesaro, Inc.19$16,034
Medtronic10$7,264
GSK1$40
Aspira Women's Health Inc1$39
Meditrina1$29
Boehringer Ingelheim1$23
Kairos Surgical Inc1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,448 in reported general payments places this provider in the 85th percentile of 25 gynecologic oncology providers in Connecticut.

See all gynecologic oncology providers in Connecticut

Medicare billing

Part B allowed, 2024
$30,652
Medicare patients
69
Services billed
151

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other gynecologic oncology in Hartford

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →